Teleflex, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US8793691069
USD
118.86
-0.26 (-0.22%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Teleflex, Inc. stock-summary
stock-summary
Teleflex, Inc.
Pharmaceuticals & Biotechnology
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM). The Company's products include oxygen therapy products, aerosol therapy products, spirometry products, and ventilation management products, which are offered under Hudson RCI brand. As of December 31, 2016, it manufactured its products at approximately 30 manufacturing sites, with manufacturing operations located in the Czech Republic, Germany, Malaysia, Mexico and the United States. Its all others businesses include single-use respiratory, urology and cardiac care products, as well as capital equipment.
Company Coordinates stock-summary
Company Details
550 E Swedesford Rd Ste 400 , WAYNE PA : 19087-1601
stock-summary
Tel: 1 610 22568001 610 9482836
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 129 Schemes (80.62%)

Foreign Institutions

Held by 274 Foreign Institutions (20.79%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Liam Kelly
Chairman of the Board, President, Chief Executive Officer
Mr. George Babich
Lead Independent Director
Ms. Candace Duncan
Independent Director
Ms. Gretchen Haggerty
Independent Director
Mr. John Heinmiller
Independent Director
Dr. Stephen Klasko
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
781 Million
(Quarterly Results - Jun 2025)
Net Profit:
123 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 5,892 Million (Small Cap)

stock-summary
P/E

13.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

1.08%

stock-summary
Debt Equity

0.38

stock-summary
Return on Equity

11.18%

stock-summary
Price to Book

1.39